Prevalence, incidence, and thromboembolic events in polycythemia vera: a study based on longitudinal German health claims data.
Ontology highlight
ABSTRACT: There is little evidence, particularly in Germany, on the epidemiology and the cytoreductive management of polycythemia vera (PV). We performed an observational study based on anonymized health claims data to provide estimates of the epidemiology of PV in Germany, to describe the use of cytoreductive drugs in patients with PV, and to assess the occurrence of thromboembolic events (TEs) in prevalent patients on continuous treatment with relevant cytoreductive drugs over time. For the year 2021, we estimated a PV prevalence of 28.6 per 100,000 and an incidence of 3.3 per 100,000 in the German adult population (≥ 18 years). We identified 83.2% of prevalent patients in 2021 as being at high risk for thromboembolic complications, based on age (≥ 60 years) and/or history of TEs. Contrary to trea
SUBMITTER: Manz KC
PROVIDER: S-EPMC11868326 | biostudies-literature | 2025 Jan
REPOSITORIES: biostudies-literature
ACCESS DATA